- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Disease and Diabetes
Lockdowns Led to Weight Gain, Increases in Stress But No Changes in Glycemic Control Among Diabetics
January 16, 2021
Data from questionnaires given to type 1 and type 2 diabetes patients from an outpatient clinic is providing insight into how the COVID-19 pandemic has impacted diabetes management.
Reducing Cardiovascular Autonomic Neuropathy Risk with Intensive Blood Pressure, Glucose Control
December 21, 2020
A retrospective analysis of more than 7k patients from the ACCORD trial suggests intensive blood pressure and intensive blood glucose control could reduce the risk of cardiovascular autonomic neuropathy in diabetics.
Bariatric Surgery in Obese Teens Provides Greater CVD Risk Reduction Than Standard Care
December 10, 2020
A comparison of data from Teen-LABS and TODAY offer insight into the effects of medical therapy alone vs bariatric surgery in obese teens with type 2 diabetes.
A Resident's Perspective: SGLT2 Inhibitors for Primary Prevention
December 08, 2020
A resident from Penn State Hershey Medical Center offers his perspective on the potential of the SGLT2 inhibitor class to transform the treatment of diabetes and cardiovascular disease among patients with diabetes.
Long-Term Glycemic Variability Tied to Increased Risk of All-Cause, Cardiovascular Death
December 05, 2020
An analysis of data from the Look AHEAD study details the associations between long-term variability of glycemic markers and increased risk of all-cause and cardiovascular mortality.
Improved Diet Could Lower Diabetes Risk by 30% in Women
December 03, 2020
Data from an analysis of more than 25k women by a team from Brigham and Women's Hospital and Harvard Medical School suggests greater adherence to a Mediterranean diet was linked to a lower risk of developing diabetes.
Chasing the Sweet Spot: Managing Diabetes in the Modern Era
November 30, 2020
With the prevalence of diabetes continuing to grow, Gregory Weiss, MD, reflects on his experience treating patients with diabetes as a cardiologist and how recent advances have impacted cardiology.
Cardiometabolic Health: Future of Care or Detracting from Endocrinology?
November 25, 2020
In this 3-part feature series, an endocrinologist, a cardiologist, and an internist tackle the topic of who should be in charge of treating patients with diabetes and whether the creation of a cardiometabolic specialty is a worthwhile endeavor.
Analysis Indicates Semaglutide Reduces MACE Regardless of Triglyceride Levels
November 23, 2020
An analysis of data from a pair of major trials indicates use of semaglutide was associated with a reduction in MACE regardless of a patient's baseline triglyceride levels.
Muthiah Vaduganathan, MD: Key Takeaways from Sotagliflozin Data
November 21, 2020
A cardiologist from Brigham and Women's Hospital offers his thoughts on the results of phase 3 SCORED and SOLOIST trials, which examined use of sotagliflozin in patients with type 2 diabetes.
Comparing Cost-Effectiveness of Antidiabetic Therapies with Cardiovascular Benefit
November 19, 2020
Gregory Weiss, MD, examines 4 studies presented at AHA Scientific Sessions 2020 comparing the cost-effectiveness of antidiabetic agents for reducing cardiovascular events.
AHA & AstraZeneca Push for Uptake of SGLT2 Inhibitors with TRANSLATE-HF Program
November 18, 2020
TRANSLATE-HF is a collaborative effort between the AHA and AstraZeneca with the goal of increasing and optimizing SGLT2 inhibitor use in US patients. Hear further insight lead author from the first of 6 TRANSLATE-HF studies, which was presented at AHA 2020.
Deepak Bhatt, MD: Sotagliflozin and Phase 3 Data from AHA 2020
November 17, 2020
Deepak Bhatt, MD, MPH, offers his thoughts on the results of SCORED and SOLOIST as well as diving deeper into the implications of the data for sotagliflozin and SGLT2 inhibitors moving forward.
George Bakris, MD: Cardiovascular Benefits of Finerenone in FIDELIO-DKD
November 17, 2020
George Bakris, MD, offers further insight into the cardiovascular outcomes analysis of FIDELIO-DKD presented at AHA 2020.
Sotagliflozin, a Dual SGLT2/1 Inhibitor, Shows Promise in Phase 3 Trials
November 17, 2020
Data from the phase 3 SOLOIST-WHF and SCORED trials suggest sotagliflozin was associated with significant reductions in death from CVD in patients with worsening heart failure and significant reductions in blood glucose levels among patients with moderate to severe kidney impairment.
TRANSLATE-HF: More than 80% of Heart Failure Patients Eligible for Dapagliflozin
November 15, 2020
An analysis of HFrEF patients from the GWTG-HF registry suggests 81% met eligibility criteria for receiving treatment with dapagliflozin.
John McMurray, MD: DAPA-CKD and Cardiorenal Protection
November 14, 2020
Professor John McMurray discusses DAPA-CKD and what insights it provides into the cardiorenal protection seen with dapagliflozin (Farxiga) use in the landmark trial.
Empagliflozin Improves Heart Failure Symptoms, Quality of Life in Heart Failure Patients
November 14, 2020
Javed Butler, MD, MPH, discusses the results of a prespecified analysis of EMPEROR-Reduced examining the effect of empagliflozin on KCCQ-CSS and heart failure symptoms.
George Bakris, MD: Improving SGLT2 Inhibitor Prescribing Practices
November 11, 2020
George Bakris, MD, discusses an AHA 2020 study that estimated the number of diabetics in the US that were considered eligible for receiving a prescription for an SGLT2 inhibitor.
Ozempic's Superior Weight Loss Not a Result of Adverse Gastrointestinal Events
November 08, 2020
Analysis of data from the SUSTAIN program suggests adverse gastrointestinal events contributed little to superior weight loss seen with semaglutide versus other GLP-1 receptor agonists.